New drug aims to outperform current therapy in Hard-to-Treat breast cancer
NCT ID NCT07678957
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study compares a new experimental drug, BL-M07D1, to an approved therapy (DS-8201) in people with a common form of advanced breast cancer (HR-positive, HER2-low). The goal is to see if the new drug can delay cancer growth or improve survival. About 120 women aged 18 to 75 with recurrent or metastatic disease will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BL-M07D1
- What this could lead to
- If BL-M07D1 works better than DS-8201, it could offer a new treatment option for people with this type of breast cancer.
- What could go wrong
- This is an early-phase trial with only 120 participants, so results may not apply to everyone. The new drug could have unexpected side effects or not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?